Orion Oyj A (ORNAV)

Helsinki
Currency in EUR
63.30
-0.40(-0.63%)
Closed·
ORNAV Scorecard
Full Analysis
Has raised its dividend for 3 consecutive years
Trading near 52-week High
Fair Value
Day's Range
62.7064.00
52 wk Range
37.0564.00
Key Statistics
Edit
Prev. Close
63.7
Open
62.7
Day's Range
62.7-64
52 wk Range
37.05-64
Volume
14.74K
Average Volume (3m)
9.28K
1-Year Change
71.01%
Book Value / Share
7.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORNAV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Orion Oyj A News & Analysis

Show more

Orion Oyj A Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex, and Dexmedetomidine products for human use. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other companies. It has discovery service and commercial license agreement with Invenra to develop bispecific antibody cancer therapeutics; and collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.

Employees
3943
Market
Finland

Compare ORNAV to Peers and Sector

Metrics to compare
ORNAV
Peers
Sector
Relationship
P/E Ratio
25.8x17.9x−0.5x
PEG Ratio
0.420.220.00
Price/Book
8.4x2.1x2.6x
Price / LTM Sales
5.6x2.0x3.1x
Upside (Analyst Target)
-22.6%48.3%
Fair Value Upside
Unlock21.3%7.6%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.47%
Dividend Yield
2.57%
Industry Median 4.26%
Annualised payout
1.64
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Apr 23, 2025
EPS / Forecast
0.44 / 0.4568
Revenue / Forecast
354.60M / 347.02M
EPS Revisions
Last 90 days

ORNAV Income Statement

FAQ

What Is the Orion Oyj A (ORNAV) Stock Price Today?

The Orion Oyj A stock price today is 63.30

What Stock Exchange Does Orion Oyj A Trade On?

Orion Oyj A is listed and trades on the Helsinki Stock Exchange stock exchange.

What Is the Stock Symbol for Orion Oyj A?

The stock symbol for Orion Oyj A is "ORNAV."

Does Orion Oyj A Pay Dividends? What’s The Current Dividend Yield?

The Orion Oyj A dividend yield is 2.59%.

What Is the Orion Oyj A Market Cap?

As of today, Orion Oyj A market cap is 8.91B.

What Is Orion Oyj A's Earnings Per Share (TTM)?

The Orion Oyj A EPS (TTM) is 2.47.

When Is the Next Orion Oyj A Earnings Date?

Orion Oyj A will release its next earnings report on 17 Jul 2025.

From a Technical Analysis Perspective, Is ORNAV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Orion Oyj A Stock Split?

Orion Oyj A has split 0 times.

How Many Employees Does Orion Oyj A Have?

Orion Oyj A has 3943 employees.

What is the current trading status of Orion Oyj A (ORNAV)?

As of 13 Jun 2025, Orion Oyj A (ORNAV) is trading at a price of 63.30, with a previous close of 63.70. The stock has fluctuated within a day range of 62.70 to 64.00, while its 52-week range spans from 37.05 to 64.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.